Select Your Region
Global
Search results
Review the results we have found for you.
Use the filters to narrow down the results list and easily find the trial you look for.
Refine your search
Search
Bladder Cancer
Location
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
We found 13 results for 'BLADDER CANCER'Use the filters to narrow down your search.
1 
Study StatusRecruiting1 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- Cancer,
- Head and Neck Cancer,
- Squamous Cell Carcinoma,
- Solid Tumors,
- Advanced Solid Tumors,
- Lung Cancer,
- Non-Small Cell Lung Cancer (NSCLC),
- Breast Cancer,
- Triple Negative Breast Cancer,
- Colorectal Cancer (CRC),
- Gastric Cancer,
- Non Small Cell Lung Carcinoma,
- Bladder Cancer,
- Urothelial Carcinoma,
- Squamous Cell Carcinoma of the Head and Neck (SCCHN),
- Esophageal Cancer,
- Hepatocellular Carcinoma (HCC),
- Metastatic Solid Tumors,
- Skin Cancer,
- Malignant Melanoma,
- Renal Cell Cancer (RCC),
- Clear Cell Renal Cell Carcinoma,
- Melanoma,
- Cervical Cancer
- NCT05581004, GO43860, 2021-006708-34
2 Study StatusRecruiting2 A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
- Cancer,
- Bladder Cancer,
- Muscle Invasive Urothelial Carcinoma
- NCT06534983, BO45230
3 
Study StatusNot yet recruiting3 A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with BGC-Unresponsive High-Risk Bladder Cancer
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
- Cancer,
- Bladder Cancer,
- Non Muscle Invasive Bladder Cancer
- NCT06816017, BP45381, 2024-515410-41-00
4 
Study StatusActive, not recruiting4 A clinical trial to look at how well atezolizumab works when taken with other drugs, compared to atezolizumab alone, in people with bladder cancer
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Cancer,
- Bladder Cancer,
- Urothelial Carcinoma
- NCT03869190, WO39613
5 Study StatusActive, not recruiting5 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
- Cancer,
- Bladder Cancer,
- Urothelial Cancer
- NCT05645692, BO44157, 2023-504027-78-00
6 Study StatusActive, not recruiting6 A clinical trial to compare the effectiveness and safety of atezolizumab with placebo in people with bladder cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
- Cancer,
- Bladder Cancer,
- Muscle-invasive Bladder Cancer
- NCT04660344, BO42843
7 Study StatusActive, not recruiting7 A study to look at how well the drug called atezolizumab works (and how safe atezolizumab is) to treat different types of cancer in the real world, outside of controlled clinical trials
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
- Cancer,
- Lung Cancer,
- Small Cell Lung Cancer,
- Non-Small Cell Lung Cancer (NSCLC),
- Non Small Cell Lung Carcinoma,
- Bladder Cancer,
- Urothelial Carcinoma,
- Hepatocellular Carcinoma (HCC)
- NCT03782207, MO40653
8 Study StatusActive, not recruiting8 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
- Cancer,
- Lung Cancer,
- Non-Small Cell Lung Cancer (NSCLC),
- Breast Cancer,
- Triple Negative Breast Cancer,
- Bladder Cancer,
- Colorectal Cancer (CRC),
- Skin Cancer,
- Malignant Melanoma,
- Renal Cell Cancer (RCC),
- Non Small Cell Lung Carcinoma,
- Melanoma,
- Head and Neck Cancer
- NCT03289962, GO39733, 2017-001475-23
9 
Study StatusCompleted9 A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
- Cancer,
- Hepatocellular Carcinoma (HCC),
- Lung Cancer,
- Non-Small Cell Lung Cancer (NSCLC),
- Breast Cancer,
- Triple Negative Breast Cancer,
- Small Cell Lung Carcinoma,
- Bladder Cancer,
- Urothelial Carcinoma
- NCT03232593, ML39313
10 Study StatusCompleted10 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- Cancer,
- Solid Tumors,
- Bladder Cancer,
- Tumor,
- Neoplasms
- NCT02091141, ML28897, PRO 02